Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ...

As a first-line therapy, the risk of disease progression or death was reduced by 55% in the pempulimab-kcqx group vs the placebo group. The Food and Drug Administration (FDA) has approved ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with ...

Loqtorzi combined with chemotherapy nearly doubled median overall survival in nasopharyngeal carcinoma patients compared to chemotherapy alone, with a median survival of 64.8 months. The combination ...

MRI showed more than 90% sensitivity in detecting nasopharyngeal carcinoma (NPC), surpassing endoscopy’s detection rate of 65.6% over a 5-year period. MRI particularly excelled in identifying ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Individuals ...

Penpulimab-kcqx is approved for first-line treatment of recurrent or metastatic non-keratinizing NPC in combination with cisplatin or carboplatin and gemcitabine. As a single agent, penpulimab-kcqx is ...

The TP63 gene, an important member of the TP53 family, contains two independent promoters that drive the transcription of TAp63 and ΔNp63, respectively. Through alternative splicing, TAp63 and ΔNp63 ...

Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial. Major pathological response to ...